GlassScriptPhysician profile
Damon S Dierker
NPI 1063453819
$706,914.86
in general payments reported to CMS, 2019-2025
49 companies · $100K in 2025
The $100K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $90K · 2021: $94K · 2022: $104K · 2023: $105K · 2024: $141K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $160K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $75K · Consulting Fee: $74K · Travel and Lodging: $19K · Food and Beverage: $19K · Entertainment: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $159,952.52 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $74,661.00 |
| Consulting Fee | $74,186.50 |
| Travel and Lodging | $19,054.83 |
| Food and Beverage | $18,796.32 |
| Entertainment | $156.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $101,643.15 | 2019-2025 | Tearcare System, Omni Surgical System |
| Bausch & Lomb Americas INC. | $84,674.16 | 2022-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Oyster Point Pharma, INC. | $84,090.83 | 2022-2025 | Tyrvaya, Phentolamine Mesylate, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $79,084.72 | 2019-2025 | Cequa |
| Allergan, INC. | $69,171.33 | 2019-2022 | |
| Alcon Vision LLC | $64,884.14 | 2019-2025 | Tryptyr, Eysuvis, Rhopressa |
| Tarsus Pharmaceuticals, INC. | $53,205.17 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $29,493.46 | 2019-2022 | |
| Tearlab Corp | $19,026.67 | 2019-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Maculogix, INC. | $18,992.84 | 2019-2021 | |
| Abbvie INC. | $16,187.96 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Biotissue Holdings INC. | $10,808.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $10,125.65 | 2019-2023 | Xiidra |
| Dompe US, INC. | $9,688.50 | 2020-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $9,364.66 | 2024-2025 | Syfovre |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $8,893.79 | 2019-2025 | Tryptyr |
| Thea Pharma INC. | $7,436.29 | 2022-2024 | Iyuzeh |
| Glaukos Corporation | $5,106.13 | 2019-2025 | Kxl System, Istent Infinite Trabecular Micro-Bypass System Model Is3, Radius |
| Lumenis, INC | $3,750.00 | 2019-2020 | |
| Shire North American Group INC | $3,411.31 | 2019 | |
| Eyevance Pharmaceuticals LLC | $2,686.63 | 2019-2022 | |
| Nordic Pharma, INC. | $2,615.00 | 2025 | Lacrifill |
| Johnson & Johnson Vision Care, INC. | $2,100.00 | 2020 | |
| Lensar, INC. | $2,074.79 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $1,022.52 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $920.84 | 2020-2025 | Veracity Surgical |
| Aerie Pharmaceuticals, INC. | $861.81 | 2019-2021 | |
| Lumenis Be INC | $800.00 | 2023 | Optilight |
| Quidel Corporation | $729.05 | 2019-2022 | |
| Ocular Therapeutix, INC. | $712.76 | 2019-2023 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $632.48 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $505.86 | 2023-2025 | Cirrus Hd-Oct |
| Harrow Eye, LLC | $437.21 | 2024-2025 | Vevye |
| Rxsight INC | $342.77 | 2020-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Notal Vision, INC. | $328.09 | 2022 | |
| Mallinckrodt Hospital Products INC. | $195.97 | 2023-2025 | Acthar |
| Optos, INC. | $156.29 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Amgen INC. | $136.67 | 2024 | Tepezza |
| Astellas Pharma US INC | $121.18 | 2023 | |
| Optovue, INC. | $116.40 | 2019 | |
| Coopervision INC. | $98.16 | 2019 | |
| Lombart Brothers, INC. | $77.03 | 2019 | |
| Lumibird Medical INC. | $51.29 | 2025 | |
| Ani Pharmaceuticals, INC. | $33.23 | 2024 | Purified Cortrophin Gel |
| Immunogen, INC. | $29.20 | 2023 | Elahere |
| Horizon Therapeutics Plc | $25.80 | 2021 | |
| Eyepoint US, INC. | $22.48 | 2021 | |
| Alimera Sciences, INC. | $20.88 | 2024 | Iluvien, Yutiq |
| Osmotica Pharmaceutical Corp. | $20.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Dierker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.